Gene Expression Score for COVID-19 Mortality Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective means to determine the risk of mortality from critical COVID-19, necessitating a reliable method to assess and monitor the disease's severity through gene expression analysis.
Innovation Solution
A method involving the measurement of gene expression levels in specific immune cells, such as CD14 monocytes, CD16 monocytes, and type II conventional dendritic cells, using a panel of genes like IFITM1, IFITM3, and CEBPD to compute a gene expression score, which is compared to a reference score to determine the risk of mortality from critical COVID-19.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If gene expression levels are measured using a panel of genes to compute a mortality risk score, then the accuracy of predicting survival in critical COVID-19 patients is improved, but the complexity of the diagnostic method increases
Solution Approach 1:
The diagnostic method is segmented into distinct components: selecting specific immune cell types (CD14 monocytes, CD16 monocytes, cDC2 cells), measuring expression of particular gene panels (IFITM1, IFITM3, CEBPD, etc.), and computing separate gene expression scores for each cell type. This segmentation allows the complex diagnostic task to be broken down into manageable, standardized steps that can be performed systematically.
Solution Approach 2:
The method utilizes changes in gene expression parameters as indicators of mortality risk. By measuring the expression levels of specific genes (such as IFITM1, IFITM3, CEBPD) in different immune cell populations and comparing these parameters against reference values, the system detects significant deviations that correlate with poor outcomes, thereby transforming molecular biological parameters into clinically actionable risk assessment.
2Reliability
If a panel of multiple genes is measured in specific immune cell types, then the reliability of mortality risk determination is improved, but the time required for analysis increases
Solution Approach 1:
The method employs preliminary action by establishing reference gene expression scores from control subjects before clinical application. These reference values (determined from healthy individuals or survivors) are pre-computed and stored, allowing rapid comparison with patient samples. This preliminary characterization of baseline expression patterns enables quick risk assessment without requiring de novo analysis of all possible gene-cell combinations.
Solution Approach 2:
The gene expression scoring system serves multiple functions: it can be applied to different immune cell types (monocytes, dendritic cells), different gene panels, and different clinical scenarios (risk stratification, treatment response monitoring). This multi-functionality increases reliability by allowing cross-validation across multiple measurement dimensions while maintaining a unified analytical framework that reduces overall analysis time.
Data Source
AI summary
Among the various aspects of the present disclosure is the provision of detecting COVID-19 severity. One aspect provides a method of predicting survival in subjects having COVID-19 (e.g., critical COVID-19) comprising single-cell RNA sequencing and Cellular Indexing of Transcriptomes and Epitomes by sequence mapping to elucidate cell type specific transcriptional signatures. Another aspect provides for a method of predicting COVID-19 infection survival comprising detecting activation of antibody processing, early activation response, and/or cell cycle regulation pathways most prominent within B-, T-, and/or NK-cell subsets. Yet another aspect provides for a method of predicting mortality in a subject having COVID-19, comprising detecting interferon signaling and antigen presentation pathways within cDC2 cells, CD14 monocytes, and/or CD16 monocytes. In some embodiments, the method comprises detecting cell specific differential gene expression and machine learning to predict mortality using single cell transcriptomes. In some embodiments, the subject is prioritized for treatment of COVID-19.